A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

NCT00857571 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: 150 mg Suspension
DRUG: 30 mg Suspension
DRUG: 400 mg Suspension
DRUG: 5 mg Suspension
DRUG: 750 mg Suspension
DRUG: 150 mg Tablet
DRUG: 30 mg Tablet
DRUG: 400 mg Tablet
DRUG: 5 mg Tablet
DRUG: 750 mg Tablet

Sponsor

Pfizer